Côd QR

Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy

Venetoclax and obinutuzumab are becoming frontline therapies for chronic lymphocytic leukemia (CLL) patients. Unfortunately, drug resistance still occurs, and the combination could be immunosuppressive. Lysosomes have previously been identified as a target for obinutuzumab cytotoxicity in CLL cells,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Madhumita S. Manivannan, Xiaoyan Yang, Nirav Patel, Anthea Peters, James B. Johnston, Spencer B. Gibson
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2024-06-01
Cyfres:Cells
Pynciau:
CLL
lysosomes
cell death
cathepsins
autophagy
Mynediad Ar-lein:https://www.mdpi.com/2073-4409/13/12/1041
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg